Kornimate/medical-research-clean huggingface dataset:
cancer-related thromboembolic disease

Conditions: Adenocarcinoma

Summary: patients with cancer are at particularly high risk of venous thromboembolism (vte). the guidelines therefore strongly recommend thromboprophylaxis but recent surveys clearly show that oncologists are reluctant to use it because of concern over bleeding, absence of validated risk stratification tools and uncertainties concerning the optimal thromboprophylaxis. hence, it is a real challenge to identify the individual vte risk of each cancer patient and individually tailor their thromboprophylaxis. the study aims to identify thrombin generation test (tgt) as a reliable, standardized overall haemostasis assay that can be used to evaluate individual thrombosis risk the secondary objectives are: * to define the limits of tgt parameters that indicate thrombosis risk in cancer patients * to evaluate values of other clotting activation markers in patients with cancer patients recently diagnosed with locally advanced or metastatic adenocarcinoma of any origin, who are scheduled for systemic chemotherapy, will be enrolled in the trial at baseline (visit 1). thrombin generating capacity will be measured within the first month following diagnosis and before the start of the chemotherapy (between visit 1 and visit 2) and subsequently at the end of the first cure line of chemotherapy (visit 3). patients will be followed up for a period of 1 year, or until the occurrence of a thromboembolic event. two follow up visits are foreseen - 6-month (visit 4) and 12-month (or at the end of trial - visit 5) visits. patients eventually undergoing second-line chemotherapy during the course of the follow-up will remain on study. the study will document all cases of symptomatic thromboembolic events together with the relevant diagnostic work-up.


Eligibility criteria:
inclusion criteria: * adult patients of both sexes with locally advanced or metastatic adenocarcinoma of any origin, who are scheduled for systemic chemotherapy * subjects having signed informed consent prior to initiation of any study procedure * covered by a health system exclusion criteria: * known bleeding or thrombophilia disorders * eastern cooperative oncology group (ecog) performance status ≥ 3 * patient immobilized * confirmed venous thromboembolism in the last 12 months * active bleeding or bleedings in the last 4 weeks requiring hospitalization, transfusion, or surgical intervention * anticoagulant therapy at the moment of first sampling (at least one day off for heparines and doac; at least 5 days off for vka is needed) * antiplatelet therapy at the moment of first sampling (only if prp tga can be performed at site) * severe hepatic insufficiency * life expectancy of less than 3 months * pregnancy

Keywords: adenocarcinoma venous thromboembolism thrombin generation assay
antidepressant decision aid for major depressive disorder patients

Conditions: Depression; Depressive Symptoms; Depressive Disorder, Major; Mood Disorders

Summary: the purpose of this study is to determine whether antidepressant decision aid for major depressive disorder is feasible and effective in involving patients in the decision-making process when initiating pharmacotherapy.

to examine the ability of the patient decision aid to enhance shared decision making and preparedness to make decisions pertaining to antidepressant therapy. the research team has systematically developed an antidepressant decision aid for major depressive disorder patients (adam) according to the international patient decision aids standards (ipdas) and the ottawa decision support framework. this is a posttest-only study with nonequivalent groups to evaluate the effect of the antidepressant decision aid on patient and physician perception of shared decision making as well as patient preparedness for making pharmacotherapeutic decisions compared usual care.

Eligibility criteria:
inclusion criteria: * diagnosed with major depressive disorder (mdd) * no psychotic symptoms * based on psychiatrist's clinical judgement currently in need for antidepressant treatment. * functional english literacy and language skills (to use the decision aid and fill out the questionnaires) * provides consent exclusion criteria: * psychosis * communication barriers (visual impairment, language barrier)

Keywords: shared decision making patient decision aid
pilot study to evaluate the effectiveness of online familiar metacognitive training (mctf)

Conditions: Psychosis; Mother-Child Relations

Summary: the objective of this study is to adapt and evaluate the efficacy of familiar metacognitive training (mctf) in mothers and adolescent children in a group context with the main purpose of improving family relationships, cognitive awareness and symptoms of women with psychosis and the knowledge of the disease by the children. secondary objectives: to evaluate the improvement in metacognition and social cognition, symptoms, protective factors and self-perception of stigma.

this is a randomized clinical trial will be carried out in which a group of mothers with psychosis and their adolescent children (between 12 and 18 years old) will receive the mctf online and the other group will receive the treatment as usual. in total, 48 mothers and their children will be recruited from a total of 11 adult mental health care centers. mothers will be evaluated with cognitive insight scales, other metacognitive and social cognition scales, symptoms, family and social functioning, protective factors (self-steem, resilience, and coping strategies) and self-perceived stigma. the adolescent children will be evaluated with symptoms, metacognition and social cognition, family and social functioning, knowledge of the mother´s illness and protective factors scales. the will be assessed at 2 times: baseline and post-therapy. the metacognitive training is a group psychological intervention that has demonstrated its efficacy in improve symptoms, insight, metacognition and cognition in people with psychosis. our hypothesis is that mctf will be help the adolescents to better understand their mother´s thoughts and their understanding of metacognition and, consequently, to decrease anxiety and depressive symptoms.furthermore, the investigators expect an increase in familiar and social functioning, as well as in protective factors such as: self-steem, resilience and coping strategies.

Eligibility criteria:
inclusion criteria: * presence of one of the following diagnoses according to dsm-v criteria: schizophrenia, unspecific psychotic disorder, schizoaffective disorder, delusional disorder, brief psychotic disorder, schizophreniform disorder. * mother of one o more adolescent (12-18 years old). * psychopatological stability in the previous 3 months.(without medication changes). exclusion criteria: * head injury or intellectual disabillity (premorbid iq \<=70) * present scores on the panss \>= hostility, lack of cooperation or suspiciousness, to guarantee a good relationship in the group. * patients with substance dependence disorder. inclusion/exclusion criteria of adolescents are: 1.age between 12 and 18 yerars old, 2. interested in the group. exclusion criteria: head injury or intellectual disabillity (premorbid iq \<=70).
routine follow up after total hip arthroplasty prior periacetabular osteotomy

Conditions: Hip Dysplasia; Osteotomy of Pelvis; Total Hip Arthroplasty

Summary: follow up study of patients, who despite periacetabular osteotomy, need a total hip arthroplasty, to see outcome.


Eligibility criteria:
inclusion criteria: * pao and tha exclusion criteria: * time since tha less than 4 yrs
impact of dihydroartemisinin-piperaquine plus primaquine on malaria transmission in lampung province, sumatra

Conditions: Malaria

Summary: artemisinin-based combination therapy (act) has been known to be controversial for stopping malaria transmission. the addition of primaquine (pq) - the only drug commercially available that kills mature transmission stage - to such treatments might be necessary to eliminate this stage. a study is conducted to evaluate the efficacy of dihydroartemisinin-piperaquine (dhp) regimens with pq on malaria transmission on a community wide level in lempasing, lampung, sumatra.

a mass screening baseline survey enabled the description of malaria prevalence (p. falciparum and p. vivax). malaria infected asymptomatic (from the mass screening) and symptomatic (malaria infected people attending the health center) people were enrolled in the study. enrolled malaria infected subjects were treated with dhp and pq according to the treatment regimen. the community was mass screened for malaria infections every 3 months and an incidence cohort screened every month for infections. the 3 aims were to look at malaria antibodies, haemoglobin levels and the incidence of malaria before and after the drug intervention.

Eligibility criteria:
inclusion criteria: * all individuals residing lempasing village, kecamatan hanura, lampung province during study period exclusion criteria: * individuals with severe or chronic disease (liver, kidney), infant and pregnant or breastfeeding woman * individuals that refuse to sign informed consent are excluded. * normal glucose-6-phosphate dehydrogenase enzyme level based on qualitative test (trinity biotech® no 203, usa) * willingness to sign the informed-consent form

Keywords: malaria dhp pq mst
intravenous magnesium infusion in patients undergoing cardioversion of atrial fibrillation trial

Conditions: Atrial Fibrillation

Summary: the proposed study is designed to evaluate the effect of an intravenous infusion of magnesium sulfate in facilitating successful cardioversion of atrial fibrillation and in decreasing the energy threshold (in j) required for successful cardioversion of atrial fibrillation into sinus rhythm.

patients with atrial fibrillation may suffer from disabling symptoms such as palpitations, shortness of breath or worsening heart failure. in such patients, it may be beneficial to convert their rhythm to sinus rhythm. cardioversion can be achieved either pharmacologically or electrically. pharmacological cardioversion is less successful acutely than electrical cardioversion and may be associated with complications such as prolongation of the qt interval and torsades de pointes (polymorphic ventricular tachycardia). thus, cardioversion is most often accomplished electrically, using biphasic synchronized shocks of 75-200 joules. biphasic electrical cardioversion in atrial fibrillation has shown to be successful (i.e., converting to sinus rhythm) about 88% of the time, on average. the success rate appears to largely depend upon the duration of the arrhythmia and the presence and severity of structural heart disease. in this study, we will evaluate the effect of intravenous magnesium sulfate on the success rate of electrical cardioversion, and also assess its effect in decreasing the energy levels needed for successful cardioversion. if the study is successful, we will have shown that a simple and inexpensive intervention can increase the success rate of electrical cardioversion, increasing the proportion of patients who can be restored to sinus rhythm. in addition, success with lower energy levels may improve the safety of cardioversion, as high energy levels are more likely to be associated with side effects

Eligibility criteria:
inclusion criteria: * patient with new onset atrial fibrillation less than 48 hours after onset undergoing electrical cardioversion. * patients with atrial fibrillation longer than 48 hours on warfarin with documented therapeutic inr levels \>2 for at least 3 weeks prior to the cardioversion, or been on dabigatran for 3 weeks, or a transesophageal echocardiogram on the day of the procedure that excludes intracardiac thrombi, undergoing electrical cardioversion. exclusion criteria: * creatinine \>2.0 mg/dl * potassium level less than 3.5 mmol/dl * tsh \< 0.5 * magnesium levels \>3.0 mg/dl * urgent need for cardioversion (e.g., hemodynamic instability, unstable angina, pulmonary edema) * patients with recent (less than 6 weeks) acute myocardial infarction * patients post-cardiac surgery * pregnant women * patients who are being treated with antiarrhythmic drugs who have received less than five doses of the drug. for amiodarone, patients who have received less than three weeks prior to cardioversion are excluded.

Keywords: atrial fibrillation electrical cardioversion magnesium sulfate
retrospective image analysis of degenerative lumbar disease patients

Conditions: Lumbar Spondylolisthesis

Summary: the dynesys dynamic stabilization (dds) system is considered a motion-preserving device. however, studies addressing the change in the range of motion (rom) are limited. therefore, this study aimed to investigate the factors influencing rom change at the index surgical level, supra-index level, and whole lumbar spine, in addition to the association between rom preservation and the incidence of screw-loosening.

decompression with instrumented fusion is an effective surgical intervention for lumbar degenerative spondylolisthesis with spinal stenosis. however, the range of motion (rom) decreased at the index surgical level may lead to an increased rom at the non-surgical level, increase biomechanical stress at the transitional adjacent segment, and lead to adjacent segment degeneration (asd) . the dynesys dynamic stabilization (dds) system is a pedicle screw-based, motion-preserving, and non-fusion stabilization developed as an alternative to the rigid instrumented fusion for degenerative spondylolisthesis. the aim of the dds is to maintain segmental motion at index levels and to reduce the incidence of asd. however, the actual impact of rom has remained elusive. prior studies have reported an average rom loss of 1.1º to 17.3º 7 at index surgical level at an average of 24 months follow-up. the change of rom at index surgical, supra-index, and whole lumbar spine following dds remains unclear. this study aims to investigate the factors influencing the rom change at index surgical level, supra-index level, and whole lumbar spine, and the association between rom preservation and the incidence of screw-loosening.

Eligibility criteria:
inclusion criteria: * adult patients * diagnosed with degenerative spondylolisthesis over l4-l5 * received dds * received a minimum of 2-year follow-up were reviewed. exclusion criteria: * presence of degenerative scoliosis or spinal deformity, * prior spine surgery, * lost to follow-up, or * failure to complete the questionnaires or radiographic examinations.

Keywords: dynesys dynamic stabilization, range of motion
study of stereotactic body radiation therapy using tomotherapy for metastatic tumors to the liver

Conditions: Liver Cancer

Summary: the purpose of this study is to determine the response of liver tumors to radiation therapy using tomotherapy.

the purpose of this study is to determine the response of liver tumors to radiation therapy. this study will be using a type of radiation therapy called tomotherapy. tomotherapy is a relatively new kind of therapy which is able to focus a large amount of radiation to a small area with relatively less radiation to the surrounding non-cancerous part of the organ. this study is being done to find out if this technique is able to control the cancer better or not than the standard radiation and also to study its safety. the usual treatment for this type of disease for patients who are eligible is surgery to remove the tumors. for patients who aren't eligible for surgery or who chose not to have surgery, they are treated with low daily doses of radiation given over many weeks; however this type of treatment has not been very effective.

Eligibility criteria:
inclusion criteria: * histologic confirmation of solid primary tumor metastatic to liver * age greater than or equal to 18 years old * zubrod performance status less than or equal to 1 * negative pregnancy test for women of child bearing potential * informed consent * less than or equal to 3 liver metastases * each lesion must be less than or equal to 6 cm in maximal diameter * no prior radiation to lesions being treated * patient is not a surgical candidate or refuses surgery * absolute neutrophil count ≥ 1800 * platelets ≥ 100000 * hemoglobin ≥8.0 * systemic therapy (chemotherapy) completed at least 2 weeks prior to sbrt * at time of radiation treatment planning, at least 700 cc of normal liver must receive less than 15 gy exclusion criteria: * contraindications to radiation * pregnant or lactating females who chose to breast feed * patients must have recovered from toxicity of prior therapy * any co morbid condition that' in the view of the attending physician' renders the patient at high risk from treatment complications * patients currently receiving anticoagulation with coumadin or iv heparin * liver cirrhosis * clinical ascites * bilirubin \> 3, albumin \ 1.8

Keywords: liver cancer metastatic liver cancer tomotherapy stereotactic body radiation therapy
normal tension and chronic open angle glaucoma and cerebrospinal fluid composition

Conditions: Glaucoma Open-Angle

Summary: normal tension glaucoma (ntg) and chronic open angle glaucoma (coag) occurring progressively with optimal conventional or intraocular pressure reducing surgery are still unsolved problems in ophthalmology. the investigators would like to investigate whether or not the composition of cerebrospinal fluid (csf) surrounding the optic nerve (on) in these patients is pathologic under certain conditions. they therefore compare the csf taken during optic nerve sheath fenestration with the csf taken during a lumbar puncture. the investigators' hypothesis is that, in patients with ntg and coag, the composition of csf surrounding the affected on plays an important role in promoting progressive visual function loss.

we will recruit 30 patients with progressive visual function loss, due to normal tension glaucoma (ntg) or chronic open angle glaucoma (coag), despite optimal conventional or intraocular pressure reducing surgery treatment so far. we will proceed with an optic nerve sheath fenestration (onsf) (according to the studies in the literature, e.g. wax mb, barrett da, hart wm jr, custer pl. optic nerve sheath decompression for glaucomatous optic neuropathy with normal intraocular pressure. arch ophthalmol. 1993;111(9):1219-28.) and compare the cerebrospinal fluid (csf) taken from the subarachnoid space (sas) of the optic nerve (on) with the csf taken during a lumbar puncture, on the same day. concentrations of neurobioactive substances will especially be studied. visual acuity and visual field development before and after onsf will be studied. quality of life assessment will be done before and several times after onsf.

Eligibility criteria:
inclusion criteria: * documented progressive visual function loss over 2 years (visual field or visual acuity) * intraocular pressure measured as a maximum of 25 mmhg * possibility of receiving general anaesthesia and optic nerve sheath fenestration. exclusion criteria: * secondary glaucoma * oral medication to lower intraocular pressure (carboanhydrase inhibitor) * visual acuity worse than 20/400 * any other type of glaucoma (pseudoexfoliation, narrow or closed angle).

Keywords: glaucoma open-angle normal tension glaucoma progressive chronic open angle glaucoma progressive optic nerve sheath fenestration cerebrospinal fluid beta-trace protein
magnetic resonance imaging study of geriatric depression

Conditions: Major Depressive Disorder

Summary: the purpose of this study was to use magnetic resonance images to further our understanding of predictors and markers of treatment response and non-response in geriatric depression. we hypothesized that concentrations of high energy metabolites would be lower in depressed elderly compared to non-depressed.


Eligibility criteria:
inclusion criteria: * dsm- iv (diagnostic and statistical manual of mental disorders, 4th edition) diagnostic criteria for major depressive disorder * hamilton depression scale- 17 item version score of 18 or higher * must speak english * women must be post-menopausal exclusion criteria: * a current or pervious psychiatric disorder other than mdd * a current unstable medical condition * a pacemaker or metal implant * history of alcohol or drug dependence or abuse within the past year * current prescription of excluded medications * use of a drug within the last 30 days that was not approved for use by governmental authorities. * if you or a family member works at mclean hospital

Keywords: depression geriatric mri sertraline
a transfer learning radiomics model for predicting response to initial transarterial embolization in patients with gastroenteropancreatic neuroendocrine tumor liver metastases

Conditions: Neuroendocrine Tumors, NET

Summary: to develop and validate a ct-based transfer learning radiomics model for predicting response to initial tae in gep-netlm patients and compare its performance with traditional radiomics and clinical models.


Eligibility criteria:
inclusion criteria: * (a) clinical diagnosed as gastroenteropancreatic neuroendocrine tumor liver metastases; (b) received initial transarterial embolization therapy; (c) underwent multi-phase cect scans pre-tae (≤1 month) and post-tae (4-6 weeks). exclusion criteria: * (a) neuroendocrine carcinoma (nec) or other malignancies. (b) received other liver metastasis treatments. (c) lack of multi-phase cect scans records. (d) ct images with artifacts or no visible lesions.
efficacy and safety study of a recombinant protein-free manufactured factor viii (rahf-pfm) in previously untreated hemophilia a patients

Conditions: Hemophilia A

Summary: the purpose of this study is to evaluate whether antihemophilic factor, recombinant, manufactured protein-free (rahf-pfm) is effective and safe in the treatment of hemophilia a patients who have not been treated with factor viii (fviii) before.


Eligibility criteria:
inclusion criteria: * the subject has severe or moderately severe hemophilia a as defined by a baseline factor viii level \<= 2% of normal, as documented at screening * the subject is \< 6 years of age * the subject's legally authorized representative has provided written informed consent exclusion criteria: * the subject has a history of exposure to factor viii other than rahf pfm or more than 3 infusions of commercially available rahf pfm (i.e., advate) within 28 days prior to screening, as determined by the subject's medical history. any infusion of factor viii replacement products prior to the 28-day period excludes the subject from participation * the subject has received more than 3 infusions of rahf pfm (commercially available and/or study product) between screening and prior to the initial recovery infusion * the subject has a detectable inhibitor to factor viii, as measured in the screening sample by the nijmegen assay in the central laboratory * the subject has a history of inhibitor to factor viii at any time prior to screening * the subject has a known hypersensitivity to rahf pfm * the subject has any 1 of the following laboratory abnormalities at the time of screening: 1. platelet count \< 100,000/mm\^3 2. hemoglobin concentration \< 10 g/dl (100 g/l) 3. serum creatinine \> 1.5 times the upper limit of normal (uln) for age 4. total bilirubin \> 2 times the uln for age * the subject has an inherited or acquired hemostatic defect other than hemophilia a (e.g., qualitative platelet defect or von willebrand's disease) * the subject is known to be seropositive for human immunodeficiency virus (hiv), hepatitis c virus (hcv), or hepatitis b virus (hbv), as determined by the subject's medical history * at the time of enrollment, the subject has a clinically significant chronic disease other than hemophilia a * the subject is currently participating in another investigational drug study, or has participated in any clinical study involving an investigational drug within 120 days of the screening visit * the subject (or the subject's legally authorized representative) is identified by the investigator as being unable or unwilling to cooperate with study procedures * the subject has received any blood product, including packed red blood cells (rbc), platelets, plasma, or cryoprecipitate

Keywords: factor viii deficiency